dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Nowak, Anna K. |
dc.contributor.author | Ellingsen, Espen Basmo |
dc.contributor.author | Farooqi, Saima Jamil |
dc.contributor.author | Bjaanæs, Maria Moksnes |
dc.contributor.author | Horndalsveen, Henrik |
dc.contributor.author | Cedres Perez, Susana |
dc.contributor.author | Haakensen, Vilde Drageset |
dc.date.accessioned | 2022-03-21T08:46:09Z |
dc.date.available | 2022-03-21T08:46:09Z |
dc.date.issued | 2021-05-31 |
dc.identifier.citation | Drageset Haakensen V, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, et al. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. J Transl Med. 2021 May 31;19:232. |
dc.identifier.issn | 1479-5876 |
dc.identifier.uri | https://hdl.handle.net/11351/7211 |
dc.description | Ipilimumab; Mesotelioma pleural maligne; Vacuna telomerasa |
dc.description.sponsorship | Ultimovacs provides UV1 vaccine and sargramostin for patients treated in arm A and some funding for the clinical trial. BMS provides ipilimumab and nivolumab for all patients. The South-Eastern Norway regional health authority has provided support for the clinical trial, PhD students and research analyses (Grant nos. 2021083 and 2020077). |
dc.language.iso | eng |
dc.publisher | BMC |
dc.relation.ispartofseries | Journal of Translational Medicine;19 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mesotelioma - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject.mesh | Mesothelioma |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | /therapeutic use |
dc.title | NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s12967-021-02905-3 |
dc.subject.decs | mesotelioma |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.1186/s12967-021-02905-3 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Haakensen VD, Farooqi SJ, Bjaanæs MM, Horndalsveen H] Department of Oncology, Oslo University Hospital, Oslo, Norway. Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. [Nowak AK] National Centre for Asbestos Related Diseases, Institute for Respiratory Health, University of Western Australia, Perth, Australia. Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Australia. [Ellingsen EB] Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. Ultimovacs, Oslo, Norway. [Cedres SM] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 34059094 |
dc.identifier.wos | 000659043100003 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |